Mupadolimab is under clinical development by Corvus Pharmaceuticals and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mupadolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mupadolimab overview

Mupadolimab (CPI-006) is under development for the treatment of non-small cell lung cancer, renal cell cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, triple negative breast cancer, colorectal cancer with microsatellite instability(MSI), bladder cancer, cervical cancer, uterine cancer, sarcoma, endometrial cancer, nasopharyngeal cancer, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, laryngeal cancer and metastatic castration-resistant prostate cancer (as a second and third line therapy) and HPV associated oropharyngeal cancer. It is administered through the intravenous route. The drug candidate is a humanized antibody which acts by targeting CD73.

It was under development for coronavirus disease 2019 (COVID-19) with mild to moderate symptoms caused by severe acute respiratory syndrome (SARS-CoV-2).

Corvus Pharmaceuticals overview

Corvus Pharmaceuticals (Corvus Pharma) is a clinical-stage biopharmaceutical company. It operates in the development and commercialization of immuno-oncology therapies that are used for treating cancer. It offers pipeline products such as CPI-818, A2A inhibitor, ciforadenant (CPI-444), mupadolimab (CPI-006) and others. Corvus Pharma’s product CPI-444 is an oral small molecule antagonist that blocks the A2A receptor. The company also develops a product candidate an anti-CD73 monoclonal antibody that inhibits the production of adenosine produced by the tumor cells. Corvus Pharma’s product pipeline also includes adenosine A2B receptor antagonists ITK inhibitors and myeloid cell suppression. The company operates in the US and the Cayman Islands. Corvus Pharma is headquartered in Burlingame, California, US.

For a complete picture of Mupadolimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.